Inclusion Criteria:

All patients:

- Histologically-confirmed advanced solid tumors

- Progressive, recurrent unresectable disease

- World Health Organization (WHO) Performance status ≤ 2

- No history of primary brain tumor or brain metastases

MTD Expansion part:

- Histologically-confirmed advanced solid tumors

- Progressive, recurrent unresectable disease

- World Health Organization (WHO) Performance status ≤ 2

- No history of primary brain tumor; no brain metastases unless asymptomatic and
clinically stable for ≥ 3 months

- Patients with genetic or molecular alteration of the PI3K pathway

Exclusion Criteria:

- Prior treatment with a PI3K inhibitor

- History of or active major depressive episode, bipolar disorder, schizophrenia, or
history of suicidal attempt or ideation

- No clinically manifest diabetes mellitus (treated and/or with clinical signs)

- No acute or chronic renal disease

- No acute or chronic liver disease

- No acute or chronic pancreatitis

- No unresolved diarrhea

- No impaired cardiac function or clinically significant cardiac diseases such as
ventricular arrhythmia, congestive heart failure, uncontrolled hypertension

- No acute myocardial infarction or unstable angina pectoris within the past 3 months

- Not pregnant or nursing and fertile patients must use barrier contraceptives

Other protocol-defined inclusion/exclusion criteria may apply